Depression pp 75-101 | Cite as

Norepinephrine Metabolism in Depressive Disorders: Implications for a Biochemical Classification of Depressions

  • Joseph J. Schildkraut
  • Paul J. Orsulak
  • Jon E. Gudeman
  • Alan F. Schatzberg
  • William A. Rohde
  • Richard A. LaBrie
  • Jane F. Cahill
  • Jonathan O. Cole
  • Shervert H. Frazier


The introduction of drugs (e.g., monoamine oxidase inhibitor antidepressants, tricyclic antidepressants and lithium salts) which proved to be effective in the treatment of depressive and manic disorders has had a major impact not only on clinical psychiatric practice but also on biological research in psychiatry. The neuropharmacology of these drugs has been studied extensively by a large number of investigators and the findings of these studies suggest that the effects of these drugs on the metabolism of the biogenic amines (i.e., the catecholamines, norepinephrine, and dopamine, as well as the indoleamine, serotonin) may be of importance clinically.1 These neuropharmacological findings served to stimulate considerable interest in biological research in the affective disorders, and many clues to the underlying pathophysiology of depressive and manic disorders have emerged from this research in recent years.2


Depressive Disorder Depressed Patient Hamilton Depression Rate Scale Hamilton Depression Rate Scale Score Somatic Anxiety 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Schildkraut JJ: Neuropsychopharmacology and the Affective Disorders. Boston, Little, Brown, 1970.Google Scholar
  2. 2.
    Schildkraut JJ: Biogenic amines and affective disorders. Ann. Rev. Med. 25:333–348, 1974.PubMedCrossRefGoogle Scholar
  3. 3.
    Schildkraut JJ: The catecholamine hypothesis of affective disorders: A review of supporting evidence. Am. J. Psychiatry 122:509–522, 1965.PubMedGoogle Scholar
  4. 4.
    Axelrod J: Noradrenaline: Fate and control of its biosynthesis. Science 173:598–606, 1971.PubMedCrossRefGoogle Scholar
  5. 5.
    Kopin IJ, Gordon EK: Metabolism of norepinephrine-H3 released by tyramine and reserpine. J. Pharmacol. Exp. Ther. 138:351–359, 1962.PubMedGoogle Scholar
  6. 6.
    Kopin IJ, Gordon EK: Metabolism of administered and drug-released norepinephrine-7-H3 in rat. J. Pharmacol. Exp. Ther. 140:207–219, 1963.PubMedGoogle Scholar
  7. 7.
    Schildkraut JJ, Green R, Gordon EK, Durell J: Normetanephrine excretion and affective state in depressed patients treated with imipramine. Am. J. Psychiatry 123:690700, 1966.Google Scholar
  8. 8.
    Prange AJ Jr., Wilson IC, Knox AE, McClane TK, Breese GR, Martin BR, Alltop LB, Lipton MA: Thyroid-imipramine clinical and chemical interaction: Evidence for a receptor deficit in depression. J. Psychiat. Res. 9:187–206, 1972.PubMedCrossRefGoogle Scholar
  9. 9.
    Maas JW, Fawcett JA, Dekirmenjian H: Catecholamine metabolism, depressive illness and drug response. Arch. Gen. Psychiatry 26:252–262, 1972.Google Scholar
  10. 10.
    Weil-Malherbe H, Axelrod J, Tomchick R: Blood-brain barrier for adrenaline. Science 129:1226–1227, 1959.PubMedCrossRefGoogle Scholar
  11. 11.
    Glowinski J, Kopin IJ, Axelrod J: Metabolism of (H3) norepinephrine in rat brain. J. Neurochem. 12:25–30, 1965.PubMedCrossRefGoogle Scholar
  12. 12.
    Schanberg SM, Schildkraut JJ, Breese GR, Kopin IJ: Metabolism of normetanephrine-H3 in rat brain-Identification of conjugated 3-methoxy-4-hydroxyphenylglycol as major metabolite. Biochem. Pharmacol. 17:247–254, 1968.PubMedCrossRefGoogle Scholar
  13. 13.
    Schanberg SM, Breese GR, Schildkraut JJ, Gordon EK, Kopin IJ: 3Methoxy-4-hydroxyphenylglycol sulfate in brain and cerebrospinal fluid. Biochem. Pharmacol. 17:2006–2008, 1968.PubMedCrossRefGoogle Scholar
  14. 14.
    Maas JW, Landis DH: In vivo studies of metabolism of norepinephrine in central nervous system. J. Pharmacol. Exp. Ther. 163:147–162, 1968.PubMedGoogle Scholar
  15. 15.
    Maas JW, Fawcett JA, Dekirmenjian H: 3-Methoxy-4-hydroxyphenylglycol (MHPG) excretion in depressive states: Pilot study. Arch. Gen. Psychiatry 19:129–134, 1968.PubMedCrossRefGoogle Scholar
  16. 16.
    Mannarino E, Kirshner N, Nashold BS Jr: Metabolism of C“ noradrenaline by cat brain in vivo. J. Neurochem. 10:373–379, 1963.CrossRefGoogle Scholar
  17. 17.
    Rutledge CO, Jonason J: Metabolic pathways of dopamine and norepinephrine in rabbit brain in vitro. J. Pharmacol. Exp. Ther. 157:493–502, 1967.Google Scholar
  18. 18.
    Wilk S, Watson E: VMA in spinal fluid: Evaluation of the pathways of cerebral catecholamine metabolism in man. In: Usdin E, Snyder S (eds) Frontiers In Catecholamine Research-Third International Catecholamine Symposium,pp. 1067–1069. New York, Pergamon, 1973.Google Scholar
  19. 19.
    Chase TN, Breese GR, Gordon EK, Kopin IJ: Catecholamine metabolism in the dog: Comparison of intravenously and intraventricularly administered (“C) dopamine and (3H) norepinephrine. J. Neurochem. 18:135–140, 1971.PubMedCrossRefGoogle Scholar
  20. 20.
    Axelrod J, Kopin IJ, Mann JD: 3-Methoxy-4-hydroxyphenylglycol sulfate, a new metabolite of epinephrine and norepinephrine. Biochim. Biophys. Acta 36:576–577, 1959.PubMedCrossRefGoogle Scholar
  21. 21.
    Maas JW, Dekirmenjian H, Garver D, Redmond DE Jr., Landis DH: Catecholamine metabolite excretion following intraventricular injection of 60H-dopamine. Brain Res. 41:507–511, 1972.PubMedCrossRefGoogle Scholar
  22. 22.
    Breese GR, Prange AJ Jr, Howard JL, Lipton MA, McKinney WT, Bowman RE, Bushnell P: 3-Methoxy-4-hydroxyphenylglycol excretion and behavioral changes in rat and monkey after central sympathectomy with 6-hydroxy-dopamine. Nature New Biol. 240:286–87, 1972.PubMedGoogle Scholar
  23. 23.
    Kopin I, Ebert M: Recent preliminary studies of the metabolism of catecholamines in the periphery and brain of human subjects. Reported at the Symposium on The Biological Deficit in the Affective Disorders, Munich, Germany, October 1974.Google Scholar
  24. 24.
    Greenspan K, Schildkraut JJ, Gordon EK, Baer L, Aranoff MS, Durell J: Catecholamine metabolism in affective disorders III. MHPG and other catecholamine metabolites in patients treated with lithium carbonate. J. Psychiat. Res. 7:171–183, 1970.PubMedCrossRefGoogle Scholar
  25. 25.
    Schildkraut JJ, Keeler BA, Rogers MP, Draskoczy PR: Catecholamine metabolism in affective disorders: A longitudinal study of a patient treated with amitriptyline and ECT. Psychosom. Med. 34:470, 1972; plus erratum: Psychosom. Med. 35:274, 1973.Google Scholar
  26. 26.
    Schildkraut JJ, Watson R, Draskoczy PR, Hartmann E: Amphetamine withdrawal: Depression and MHPG excretion. Lancet ii:485–486, 1971.CrossRefGoogle Scholar
  27. 27.
    Watson R, Hartmann E, Schildkraut JJ: Amphetamine withdrawal: Affective state, sleep patterns and MHPG excretion. Am. J. Psychiatry 129:263–269, 1972.PubMedGoogle Scholar
  28. 28.
    Bond PA, Jenner FA, Sampson GA: Daily variations of the urine content of 3-methoxy-4-hydroxyphenylglycol in two manic-depressive patients. Psycho. Med. 2:81–85, 1972.CrossRefGoogle Scholar
  29. 29.
    Jones FD, Maas JW, Dekirmenjian H, Fawcett JA: Urinary catecholamine metabolites during behavioral changes in a patient with manic-depressive cydes. Science 179:300–302, 1973.Google Scholar
  30. 30.
    Bunney WE Jr, Goodwin FK, Murphy DL, House KM, Gordon EK: The “switch process” in manic-depressive illness. Arch. Gen. Psychiatry 27:304–309, 1972.PubMedCrossRefGoogle Scholar
  31. 31.
    Shopsin B, Wilk W, Gershon S, Roffman M, Goldstein M: Collaborative psychopharmacologic studies exploring catecholamine metabolism in psychiatric disorders. In: Usdin E, Snyder S (eds) Frontiers in Catecholamine Research-Third International Catecholamine Symposium, pp. 1173–1179. New York, Pergamon, 1973.Google Scholar
  32. 32.
    Schildkraut JJ, Keeler BA, Papousek M, Hartmann E: MHPG excretion in depressive disorders: Relation to clinical subtypes and desynchronized sleep. Science 181:762–764, 1973.PubMedCrossRefGoogle Scholar
  33. 33.
    Schildkraut JJ, Keeler BA, Grab EL, Kantrowich J, Hartmann E: MHPG excretion and clinical dassification in depressive disorders. Lancet i:1251–1252, 1973.CrossRefGoogle Scholar
  34. 34.
    Schildkraut JJ, Klein DF: The classification and treatment of depressive disorders. In: Shader RI (ed) Manual of Psychiatric Therapeutics, pp. 39–61. Boston, Little, Brown, 1975.Google Scholar
  35. 35.
    Ebert MH, Post RM, Goodwin FK: Effect of physical activity on urinary MHPG excretion in depressed patients. Lancet ii:766, 1972.Google Scholar
  36. 36.
    Maas JW, Dekirmenjian H, Fawcett J: Catecholamine metabolism, depression and stress. Nature 230:330–331, 1971.PubMedCrossRefGoogle Scholar
  37. 37.
    Rubin RT, Miller RG, Clark BR, Poland RE, Arthur RJ: The stress of aircraft carrier landings II. 3-Methoxy-4-hydroxyphenylglycol excretion in naval aviators. Psychosom. Med. 32:589–597, 1970.PubMedGoogle Scholar
  38. 38.
    Hamilton M: A rating scale for depression. J. Neural. Neurosurg. Psychiatry 23:56–62, 1960.CrossRefGoogle Scholar
  39. 39.
    Schildkraut JJ: Catecholamine metabolism and affective disorders: Studies of MHPG excretion. In: Usdin E, Snyder S (eds) Frontiers In Catecholamine Research-Third International Catecholamine Symposium, pp. 1165–1171. New York, Pergamon, 1973.Google Scholar
  40. 40.
    Maas JW, Dekirmenjian H, Jones F: The identification of depressed patients who have a disorder of norepinephrine metabolism and/or disposition. In: Usdin E, Snyder S (eds) Frontiers in Catecholamine Research-Third International Catecholamine Symposium,pp. 1091–1096. New York, Pergamon, 1973.Google Scholar
  41. 41.
    Schildkraut JJ: Mania-depression rating scale, unpublished, 1961.Google Scholar
  42. 42.
    Hartmann E: Longitudinal studies of sleep and dream patterns in manic-depressive patients. Arch. Gen. Psychiatry 19:312–329, 1968.CrossRefGoogle Scholar
  43. 43.
    Detre T, Himmelhoch J, Swartzburg M, Anderson CM, Byck R, Kupfer DJ: Hypersomnia and manic-depressive disease. Am. J. Psychiatry 128:1303–1305, 1972.PubMedGoogle Scholar
  44. 44.
    Kupfer DJ, Himmelhoch JM, Swartzburg M, Anderson C, Byck R, Detre TP: Hypersomnia in manic-depressive disease. Dis. Nerv. Syst. 33:720–724, 1972.PubMedGoogle Scholar
  45. 45.
    Goodwin FK, Beckmann H, Post RM: Urinary methoxy-4-hydroxyphenylglycol in subtypes of affective illness. Scientific Proceedings, Annual Meeting, American Psychiatric Association, pp. 96–97, 1975.Google Scholar
  46. 46.
    Jones FD, Maas JW, Dekirmenjian H, Sanchez J: Diagnostic subtypes of affective disorders and their urinary excretion of catecholamine metabolites. Am. J. Psychiatry 132:1141–1148, 1975.Google Scholar
  47. 47.
    Murphy DL, Wyatt RJ: Reduced monoamine oxidase activity in blood platelets from schizophrenic patients. Nature 238:225–226, 1972.PubMedCrossRefGoogle Scholar
  48. 48.
    Schildkraut JJ, Herzog JM, Orsulak PJ, Edelman SE, Shein HM, Frazier SH: Reduced platelet monoamine oxidase activity in a subgroup of schizophrenic patients. Am. J. Psychiatry 133:438–440, 1976.PubMedGoogle Scholar
  49. 49.
    Murphy DL, Weiss R: Reduced monoamine oxidase activity in blood platelets from bipolar depressed patients. Am. J. Psychiatry 128:1351–1357, 1972.PubMedGoogle Scholar
  50. 50.
    Nies A, Robinson DS, Ravaris CL, Davis JM: Amines and monoamine oxidase in relation to aging and depression in man. Psychosom. Med. 33:470, 1971.Google Scholar
  51. 51.
    Schildkraut JJ: Norepinephrine metabolites as biochemical criteria for classifying depressive disorders and predicting responses to treatment: Preliminary findings. Am. J. Psychiatry 130:695–699, 1973.PubMedGoogle Scholar
  52. 52.
    Beckmann H, Goodwin FK: Antidepressant response to tricyclics and urinary MHPG in unipolar patients: Clinical response to imipramine or amitriptyline. Arch. Gen. Psychiatry 32:17–21, 1975.PubMedCrossRefGoogle Scholar
  53. 53.
    Schildkraut JJ, Dodge GA, Logue, MA: Effects of tricyclic antidepressants on the uptake and metabolism of intracisternally administered norepinephrine-H3 in rat brain. J. Psychiat. Res. 7:29–34, 1969.PubMedCrossRefGoogle Scholar
  54. 54.
    Schildkraut JJ, Draskoczy PR, Gershon ES, Reich P, Grab EL: Effects of tricyclic antidepressants on norepinephrine metabolism: Basic and clinical studies. In: Ho BT, McIsaac WM (eds) Brain Chemistry and Mental Disease, pp. 215–236. New York, Plenum, 1971.Google Scholar
  55. 55.
    Schildkraut JJ, Draskoczy PR, Gershon ES, Reich P, Grab EL: Catecholamine metabolism in affective disorders IV. Preliminary studies of norepinephrine metabolism in depressed patients treated with amitriptyline. J. Psychiat. Res. 9:173185, 1972.Google Scholar
  56. 56.
    LaBrie RA: Incidence analyses, unpublished.Google Scholar
  57. 57.
    Schildkraut JJ, LaBrie RA: Catecholamines and classification of depressions. New Research Abstracts, American Psychiatric Association Annual Meeting, p. 17, 1974.Google Scholar
  58. 58.
    Rosenblatt S, Chanley JD: Differences in metabolism of norpinephrine in depressions: Effects of various therapies. Arch. Gen. Psychiatry 13:495–502, 1965.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1978

Authors and Affiliations

  • Joseph J. Schildkraut
    • 1
    • 2
    • 3
  • Paul J. Orsulak
    • 1
    • 2
    • 3
  • Jon E. Gudeman
    • 1
    • 2
    • 3
  • Alan F. Schatzberg
    • 1
    • 2
    • 3
  • William A. Rohde
    • 1
    • 2
    • 3
  • Richard A. LaBrie
    • 1
    • 2
    • 3
  • Jane F. Cahill
    • 1
    • 2
    • 3
  • Jonathan O. Cole
    • 1
    • 2
    • 3
  • Shervert H. Frazier
    • 1
    • 2
    • 3
  1. 1.Department of PsychiatryHarvard Medical SchoolUSA
  2. 2.Neuropsychopharmacology LaboratoryMassachusetts Mental Health CenterBostonUSA
  3. 3.McLean HospitalBelmontUSA

Personalised recommendations